SCHEMBL5110157

SCHEMBL5110157

Nc1nc(Nc2ccc(S(=O)(=O)O)cc2)nn1C(=O)c1c(F)cccc1F

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK1 P06493 11/20 0.83
▸ JAK1 P23458 9/20 0.83
▸ TYK2 P29597 9/20 0.83
▸ CDK2 P24941 8/20 0.83
▸ JAK3 P52333 7/20 0.83
▸ JAK2 O60674 6/20 0.83
▸ CCNB2 O95067 4/20 0.83
▸ CCNB1 P14635 4/20 0.83
▸ CCNB3 Q8WWL7 4/20 0.83
▸ EIF2AK2 P19525 2/20 0.83
▸ PLK4 O00444 1/20 0.83
▸ STK25 O00506 1/20 0.83
▸ RIOK3 O14730 1/20 0.83
▸ AURKA O14965 1/20 0.83
▸ GAK O14976 1/20 0.83
▸ DCLK1 O15075 1/20 0.83
▸ PDPK1 O15530 1/20 0.83
▸ DAPK3 O43293 1/20 0.83
▸ NUAK1 O60285 1/20 0.83
▸ ROCK2 O75116 1/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Jnj-7706621 SCHEMBL1060773 0.91 CDK1 (1.00) CDK1JAK1TYK2CDK2JAK3
SCHEMBL7092328 0.88 CDK1 (0.78) CDK1JAK1TYK2CDK2JAK3
SCHEMBL5726498 0.87 CDK1 (0.71) CDK1JAK1TYK2CDK2JAK3
SCHEMBL5725874 0.87 CDK1 (0.77) CDK1JAK1TYK2CDK2JAK3
SCHEMBL14288368 0.87 CDK1 (1.00) CDK1JAK1TYK2CDK2JAK3
SCHEMBL14288380 0.86 JAK1 (1.00) CDK1JAK1TYK2CDK2JAK3
SCHEMBL5964645 0.85 JAK1 (0.74) CDK1JAK1TYK2CDK2JAK3
SCHEMBL7089472 0.85 CDK1 (0.78) CDK1JAK1TYK2CDK2JAK3
SCHEMBL31105655 0.85 CDK1 (0.82) CDK1JAK1TYK2CDK2JAK3
SCHEMBL5726847 0.84 CDK1 (0.86) CDK1JAK1TYK2CDK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7317031-B2 Substituted triazole diamine derivatives as kinase inhibitors ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2008-01-08 — — US disclosed
US-7317031-B2 Substituted triazole diamine derivatives as kinase inhibitors ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2008-01-08 — — US disclosed
US-7317031-B2 Substituted triazole diamine derivatives as kinase inhibitors ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2008-01-08 — — US disclosed
EP-1712550-A2 Substituted triazole diamine derivatives as kinase inhibitors Ortho-McNeil Pharmaceutical, Inc. (US) 2006-10-18 — — EP disclosed
US-20050182116-A1 Substituted triazole diamine derivatives as kinase inhibitors LIN RONGHUI (US) 2005-08-18 — — US disclosed
US-6924302-B2 Substituted triazole diamine derivatives as kinase inhibitors ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2005-08-02 — — US disclosed
US-20040077699-A1 Substituted triazole diamine derivatives as kinase inhibitors ORTHO-MCNEIL PHARMACEUTICAL, INC. 2004-04-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182116-A1 Substituted triazole diamine derivatives as kinase inhibitors MAP2K2, PRKDC, MAP2K3 CDK1 387/4885JAK1 349/4885TYK2 414/4885
US-20040077699-A1 Substituted triazole diamine derivatives as kinase inhibitors MAP2K2, PRKDC, MAP2K3 CDK1 387/4885JAK1 349/4885TYK2 414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback